Lannett Company, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lannett Company, Inc.
Cipla's Advair Generic US Debut May Be Pushed Out But 'Value Intact'
Cipla to pursue two-site, de-risked filing approach for large respiratory assets even as it awaits an FDA compliance classification for its Indore facility, which will determine the launch timelines for its much-awaited generic Advair in the US.
Lannett Gears Up For Chapter 11 Bankruptcy, Lenders To Take Ownership
Lannett had cautioned that a major restructuring was likely as its operations and balance sheet faltered under a massive debt pile – now that has become a reality, under a proposed plan that will hand the company keys to lenders.
Lannett Shares Banished From NYSE, Trading OTC
Lannett investors and creditors must brace for further bad news after the Philadelphia-based Rx and OTC drug firm was struck from the New York Stock Exchange.
Lannett Heads To The Pink Sheets As Financial Woes Continue
Lannett investors and creditors must brace for further bad news after the Philadelphia-based player was struck from the New York Stock Exchange.
- Generic Drugs
- Other Names / Subsidiaries
- Kremers Urban Pharmaceuticals, Cody Laboratories, Silarx Pharmaceuticals
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.